ADRB3: Beta-3 adrenergic receptor
G protein-coupled receptor for catecholamines that couples to both G(s) and G(i) proteins, leading to either activation or inhibition of adenylate cyclase and cAMP-dependent pathway, respectively.
- Drugs that act on it: 7
- Approved: 2
- In phases 1 to 3: 5
- Sponsors: 6
Who is on it, and how far along
Every drug ChEMBL records acting on ADRB3, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 7
Sponsors
Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.
- APGDI114%
- Eli Lilly114%
- Kissei Pharmaceutical Co., Ltd.114%
- Sanofi114%
- Sumitomo Pharma114%
- Velicept Therapeutics, Inc.114%
The landscape
Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Beta-3 adrenergic receptor agonist.| Mirabegron | Approved | APGDI | Small molecule | Agonist | 33 |
| Vibegron | Approved | Sumitomo Pharma | Small molecule | Agonist | 4 |
| Amibegron | Phase 3 | Sanofi | Small molecule | Agonist | 0 |
| Ritobegron | Phase 3 | Kissei Pharmaceutical Co., Ltd. | Small molecule | Agonist | 0 |
| LY377604 | Phase 2 | Eli Lilly | Small molecule | Agonist | 0 |
| Rafabegron | Phase 2 | — | Small molecule | Agonist | 0 |
| Solabegron | Phase 2 | Velicept Therapeutics, Inc. | Small molecule | Agonist | 0 |
Open trials
The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 11 in all, from ClinicalTrials.gov.Diseases most associated with it
Open Targets association score, 0 to 1; all associations- Hypertensive disorder
- 0.61
- Heart failure
- 0.61
- Asthma
- 0.60
- Congestive heart failure
- 0.59
- Sudden cardiac arrest
- 0.59
- Pain
- 0.58
- Sepsis
- 0.58
- Cardiovascular disorder
- 0.58
- Sinusitis
- 0.58
- Hypotensive disorder
- 0.57
Genes and related targets
Complexes and families that share a gene with this target- Genes
- ADRB3
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL246, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P13945, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets